FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013457720> ?p ?o ?g. }

• W2013457720 endingPage "950" @default.
• W2013457720 startingPage "941" @default.
• W2013457720 abstract "1 Platelet-activating factor (PAF) is a phospholipid mediator with potent cardiovascular and haematological actions. But its mechanisms of action in vivo have not been fully elucidated, probably due to difficulties arising from previous findings that the effects of PAF are largely mediated by the release of a variety of other autacoids. In the present study, the roles of nitric oxide and eicosanoids in the effects of PAF (0.01-0.25 μg kg−1 i.v.) on systemic and pulmonary vasculatures and circulating blood cell count were pharmacologically evaluated in anaesthetized dogs. 2 Higher doses of PAF (>0.1 μg kg−1) produced a biphasic systemic hypotension. The first hypotension seen 30 s after the injection was accompanied by a decrease in systemic vascular resistance, thrombocytopenia and leukopenia, while the second hypotension seen 1–2 min after PAF was accompanied by a marked rise in pulmonary vascular resistance and decreases in aortic blood flow and cardiac contractility. Lower doses of PAF (0.01-0.05 μg kg−1) caused only the first responses in a dose-dependent manner. 3 Pretreatment with indomethacin inhibited the second responses to PAF without affecting the first responses. The thromboxane A2/prostaglandin H2 (TP)-receptor antagonist vapiprost blocked the PAF-induced rise in pulmonary vascular resistance. AA-861, a 5-lipoxygenase inhibitor, attenuated the PAF-induced cardiac depression. The nitric oxide synthase inhibitor NG-nitro-l-arginine methyl ester inhibited the PAF-induced early decrease in systemic vascular resistance. 4 All observed changes in haemodynamics and blood cell count after PAF were almost abolished by TCV-309, a PAF-receptor antagonist. 5 Reproducible hypotension and thrombocytopenia produced by a lower dose of PAF (0.05 μg kg−1) were respectively attenuated and potentiated by pretreatment with NG-nitro-l-arginine, another nitric oxide synthase inhibitor. Administration of l-arginine reversed the effects of the nitric oxide synthase inhibitor. 6 These results indicate that PAF-receptor-mediated production of not only eicosanoids but also nitric oxide may contribute to the cardiovascular and haematological responses to PAF in the dog." @default.
• W2013457720 created "2016-06-24" @default.
• W2013457720 creator A5004003183 @default.
• W2013457720 creator A5005748766 @default.
• W2013457720 creator A5016190508 @default.
• W2013457720 creator A5024723214 @default.
• W2013457720 creator A5059523191 @default.
• W2013457720 date "1996-06-01" @default.
• W2013457720 modified "2023-10-16" @default.
• W2013457720 title "Involvement of nitric oxide and eicosanoids in platelet-activating factor-induced haemodynamic and haematological effects in dogs" @default.
• W2013457720 cites W1480177379 @default.
• W2013457720 cites W1557110126 @default.
• W2013457720 cites W1608649721 @default.
• W2013457720 cites W1834041853 @default.
• W2013457720 cites W1899256833 @default.
• W2013457720 cites W1913916639 @default.
• W2013457720 cites W1929009802 @default.
• W2013457720 cites W1984590687 @default.
• W2013457720 cites W1986305114 @default.
• W2013457720 cites W1991326779 @default.
• W2013457720 cites W2000992981 @default.
• W2013457720 cites W2003639623 @default.
• W2013457720 cites W2004088054 @default.
• W2013457720 cites W2007737411 @default.
• W2013457720 cites W2010340451 @default.
• W2013457720 cites W2014020386 @default.
• W2013457720 cites W2016051580 @default.
• W2013457720 cites W2023371009 @default.
• W2013457720 cites W2030522109 @default.
• W2013457720 cites W2033441380 @default.
• W2013457720 cites W2033794533 @default.
• W2013457720 cites W2033899018 @default.
• W2013457720 cites W2041965283 @default.
• W2013457720 cites W2043968848 @default.
• W2013457720 cites W2050057939 @default.
• W2013457720 cites W2059134103 @default.
• W2013457720 cites W2063630015 @default.
• W2013457720 cites W2065816280 @default.
• W2013457720 cites W2080363523 @default.
• W2013457720 cites W2088096519 @default.
• W2013457720 cites W2094526532 @default.
• W2013457720 cites W2157999606 @default.
• W2013457720 cites W2164381397 @default.
• W2013457720 cites W2225238109 @default.
• W2013457720 cites W2229309923 @default.
• W2013457720 cites W2261984195 @default.
• W2013457720 cites W2282317330 @default.
• W2013457720 cites W2297959303 @default.
• W2013457720 cites W2416944255 @default.
• W2013457720 cites W2472031547 @default.
• W2013457720 doi "https://doi.org/10.1111/j.1476-5381.1996.tb15490.x" @default.
• W2013457720 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1909540" @default.
• W2013457720 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8799566" @default.
• W2013457720 hasPublicationYear "1996" @default.
• W2013457720 type Work @default.
• W2013457720 sameAs 2013457720 @default.
• W2013457720 citedByCount "9" @default.
• W2013457720 countsByYear W20134577202012 @default.
• W2013457720 countsByYear W20134577202015 @default.
• W2013457720 crossrefType "journal-article" @default.
• W2013457720 hasAuthorship W2013457720A5004003183 @default.
• W2013457720 hasAuthorship W2013457720A5005748766 @default.
• W2013457720 hasAuthorship W2013457720A5016190508 @default.
• W2013457720 hasAuthorship W2013457720A5024723214 @default.
• W2013457720 hasAuthorship W2013457720A5059523191 @default.
• W2013457720 hasBestOaLocation W20134577201 @default.
• W2013457720 hasConcept C126322002 @default.
• W2013457720 hasConcept C134018914 @default.
• W2013457720 hasConcept C149588370 @default.
• W2013457720 hasConcept C170493617 @default.
• W2013457720 hasConcept C178853913 @default.
• W2013457720 hasConcept C181199279 @default.
• W2013457720 hasConcept C185592680 @default.
• W2013457720 hasConcept C2776352991 @default.
• W2013457720 hasConcept C2776785769 @default.
• W2013457720 hasConcept C2777622882 @default.
• W2013457720 hasConcept C2778078955 @default.
• W2013457720 hasConcept C2779020240 @default.
• W2013457720 hasConcept C2781024287 @default.
• W2013457720 hasConcept C39133596 @default.
• W2013457720 hasConcept C519581460 @default.
• W2013457720 hasConcept C55493867 @default.
• W2013457720 hasConcept C58245268 @default.
• W2013457720 hasConcept C71924100 @default.
• W2013457720 hasConcept C89560881 @default.
• W2013457720 hasConcept C98274493 @default.
• W2013457720 hasConceptScore W2013457720C126322002 @default.
• W2013457720 hasConceptScore W2013457720C134018914 @default.
• W2013457720 hasConceptScore W2013457720C149588370 @default.
• W2013457720 hasConceptScore W2013457720C170493617 @default.
• W2013457720 hasConceptScore W2013457720C178853913 @default.
• W2013457720 hasConceptScore W2013457720C181199279 @default.
• W2013457720 hasConceptScore W2013457720C185592680 @default.
• W2013457720 hasConceptScore W2013457720C2776352991 @default.
• W2013457720 hasConceptScore W2013457720C2776785769 @default.
• W2013457720 hasConceptScore W2013457720C2777622882 @default.
• W2013457720 hasConceptScore W2013457720C2778078955 @default.
• W2013457720 hasConceptScore W2013457720C2779020240 @default.

• next